PTC Therapeutics, Inc. | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (38)

View All

Latest Posts

About This Stock More About This Stock
Chart Of The Day: PTC Therapeutics
Article By: Jim Van Meerten
Thursday, May 18, 2023 12:05 PM EDT
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for patients with rare disorders.
In this article: PTCT
Read
Hedge Funds Have Never Been This Bullish On PTC Therapeutics, Inc. (PTCT)
Article By: Insider Monkey
Thursday, December 5, 2019 7:16 PM EDT
Here's a peek at the fresh hedge fund action surrounding PTC Therapeutics, Inc.
In this article: PTCT Also: NG, EURN, NSA, CNNE
Read
A Peek Into Latest 13-F Filing: Top Hedge Fund Stocks
Article By: Sweta Killa
Friday, May 18, 2018 9:08 PM EDT
Investors are mulling over the top bets of big investors like Bill Ackman, George Soros, Carl Icahn, David Tepper, Larry Robbins, Leon Cooperman, Daniel Loeb, David Einhorn and Stanley Druckenmiller, following the first-quarter release of 13F Forms.
In this article: EA, AAPL, ADBE, AMZN, MSFT, NFLX, META, GOOGL, TWX, UNH, ANTM, CVS, ESRX, GRBK, TUSK, GHDX, ZGNX, RTRX, PCRX, PTCT, CORI, SBBP
Read
3 Biotech And Pharma Stocks With Key FDA Catalysts This October
Article By: Arpita Dutt
Monday, October 2, 2017 10:16 AM EDT
The FDA, which approved 22 novel drugs last year, has given its approval to 34 drugs so far in 2017 including three in September.
In this article: FLXN, ALXN, PTCT Also: JNJ, TSRO, ACRX, AERI
Read
XBI Breaks Through On A Strong Week For Biotech
Article By: Rod Raynovich
Friday, September 29, 2017 7:25 PM EDT
The XBI is up 3.17% this week, 46% YTD, compared to only 1.1% WTD for the IBB. The breakthrough gains for the XBI can be attributed to strong performance of top ten holdings that are primarily mid-caps and M&A prospects.
In this article: BMY, ALNY, BMRN, IBB, AMGN, CELG, CLVS, XBI, JUNO, PBYI, SRPT, BLUE, PTCT, ABBV, FMI
Read
All Posts

Latest Tweets for $PTCT

No tweets yet!

PARTNER HEADLINES